Saturday 17 October 2026
Export NAMS’s income statement to Excel — free account
NewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024. In the quarter to June 2026, revenue fell 80.7%, EPS fell 246.7% and free cash flow fell 4.07%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
19.83
0.79
−3.83%
Follow NAMS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 9.56 | 7.52 | 5.63 | 11.18 | 14.06 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 12.39 | 32.88 | 18.70 | 27.29 | 42.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 4 | 3 | 17 | 29 | 68 | 100 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 6.04 | 0.49 | 0.67 | 0.23 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 103 | 14 | 46 | 23 | ||||
| Gross margin, % | — | — | — | — | — | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | 0 | 4 | (23) | (177) | (242) | (204) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | (22.04) | (1,255.57) | (530.25) | (905.74) | |||||
| Net income | — | 0 | — | — | 0 | 4 | (23) | (177) | (242) | (204) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 5.41 | 0.17 | 0.48 | 0.19 | ||||
| Earnings | — | — | — | — | 0.01 | 1.21 | (1.01) | (2.15) | (2.56) | (1.72) | |||||
| Cash flow | — | — | — | — | (0.16) | (0.04) | 0.56 | (1.72) | (1.68) | (1.25) | |||||
| Capex | — | — | — | — | 0.00 | (0.01) | (0.01) | 0.00 | (0.01) | 0.00 | |||||
| Free cash flow | — | — | — | — | (0.16) | (0.05) | 0.55 | (1.72) | (1.69) | (1.25) | |||||
| Book value | — | — | — | — | (3.39) | (1.84) | 22.68 | 3.51 | 8.03 | 5.77 | |||||
| Shares, m | — | — | — | — | 3 | 3 | 19 | 82 | 94 | 118 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | 0.00 | 43.24 | 53.22 | 184.61 | |||||
| P/B | — | — | — | — | — | — | 0.49 | 3.40 | 3.20 | 6.08 | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 28.25 | 34.91 | 156.28 | |||||
| EV/FCF | — | — | — | — | — | — | (23.94) | (4.54) | (9.99) | (23.76) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | 0 | 11 | (141) | (159) | (148) | ||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | (1) | 0 | |||||
| Free cash flow | — | — | — | — | (1) | 0 | 10 | (141) | (159) | (148) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 2 | 1 | 442 | 297 | 756 | 590 | ||||
| Total debt | — | — | — | — | — | 0 | 0 | — | — | — | |||||
| Net debt | — | — | — | — | (1) | (1) | (468) | (340) | (834) | (638) | |||||
| Shareholders’ equity | — | — | — | — | (11) | (6) | 430 | 288 | 758 | 683 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.03 | 2.99 | (7.32) | (42.86) | (39.88) | (24.95) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (307.51) | |||||
| ROE | — | — | — | — | 0.07 | (49.46) | (10.68) | (49.25) | (46.20) | (28.29) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
NewAmsterdam Pharma Company N.V. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ZLAB Zai Lab Limited Unsponsored ADR | $2.7B | — (loss-making) | — (loss-making) | −3.33% (below 0%: shrinking) | n/m | −84.42% (below 0%: shrinking) | 54.70% | (71.95%) | Compare |
| PGEN Precigen, Inc. | $2.6B | — (loss-making) | — (loss-making) | +6,322.66% (above 0%: growing) | n/m | +8.73% (above 0%: growing) | 94.90% | 41.18% | Compare |
| BEAM Beam Therapeutics Inc. | $2.6B | — (loss-making) | — (loss-making) | −94.21% (below 0%: shrinking) | n/m | +13.92% (above 0%: growing) | 100.00% | (25,827.14%) | Compare |
| NAMS NewAmsterdam Pharma Company N.V. | $2.5B | — (loss-making) | — (loss-making) | −80.67% (below 0%: shrinking) | n/m | −4.07% (below 0%: shrinking) | 100.00% | (1,752.61%) | |
| MBX MBX Biosciences, Inc. | $2.4B | — (loss-making) | — | — | n/m | −29.67% (below 0%: shrinking) | — | 0.00% | Compare |
| ADMA ADMA Biologics Inc | $2.4B | 14.8× | 9.5× | +1.98% (above 0%: growing) | +21.43% (above 0%: growing) | +19.72% (above 0%: growing) | 69.36% | 42.16% | Compare |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | — (loss-making) | — (loss-making) | −57.10% (below 0%: shrinking) | n/m | −3.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CLDX Celldex Therapeutics, Inc. | $2.3B | — (loss-making) | — (loss-making) | −96.83% (below 0%: shrinking) | n/m | −35.45% (below 0%: shrinking) | 100.00% | (366,468.18%) | Compare |
| AUPH Aurinia Pharmaceuticals Inc | $2.2B | 6.9× | 16.5× | +18.87% (above 0%: growing) | +81.25% (above 0%: growing) | +19.08% (above 0%: growing) | 92.12% | 48.19% | Compare |
| Median of peers | $2.4B | — | — | −3.33% | — | +2.61% | 92.12% | 0.00% |
NewAmsterdam Pharma Company N.V. (NAMS) key facts
- Concern: NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- NewAmsterdam Pharma Company N.V. (NAMS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, NAMS traded at $19.83, a market capitalization of $2.5 billion.
- Return on equity was −28.3% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 27.63 (safe zone) for fiscal 2025.